Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Irinotecan × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 364 Rectal Neoplasms 138 Colonic Neoplasms 137 Pancreatic Neoplasms 104 Stomach Neoplasms 102 Neoplasm Metastasis 78 Neoplasms 68 Esophageal Neoplasms 56 Small Cell Lung Carcinoma 42 Neuroblastoma 38 Lung Neoplasms 37 Glioblastoma 37 Carcinoma, Non-Small-Cell Lung 32 Unspecified Adult Solid Tumor, Protocol Specific 30 Brain Neoplasms 30 Esophageal Squamous Cell Carcinoma 29 Glioma 27 Breast Neoplasms 26 Adenocarcinoma Of Esophagus 25 Central Nervous System Neoplasms 24 Sarcoma 23 Gliosarcoma 21 Rhabdomyosarcoma 20 Sarcoma, Ewing 18 Astrocytoma 18 Adenocarcinoma 16 Gastrointestinal Neoplasms 15 Recurrence 14 Oligodendroglioma 14 Medulloblastoma 12

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡